a member of the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance through the cell cycle. Cyclins function as regulators of CDK kinases. Forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition. This protein has been shown to interact with tumor suppressor protein Rb and the expression of this gene is regulated positively by Rb. Note: This description may include information from UniProtKB.
Protein type: Nuclear receptor co-regulator; Activator; Cell cycle regulation; Oncoprotein
Molecular Function: cyclin-dependent protein kinase regulator activity; enzyme binding; histone deacetylase binding; protein binding; protein complex binding; protein kinase activity; protein kinase binding; transcription corepressor activity; transcription factor binding
Biological Process: cell division; establishment and/or maintenance of chromatin architecture; fat cell differentiation; G1 DNA damage checkpoint; G1/S transition of mitotic cell cycle; lactation; Leydig cell differentiation; liver development; mammary gland epithelial cell proliferation; mitotic cell cycle; negative regulation of epithelial cell differentiation; negative regulation of transcription from RNA polymerase II promoter; negative regulation of Wnt receptor signaling pathway; Notch signaling pathway; organ regeneration; positive regulation of cyclin-dependent protein kinase activity; positive regulation of mammary gland epithelial cell proliferation; positive regulation of protein amino acid phosphorylation; protein amino acid phosphorylation; re-entry into mitotic cell cycle; response to calcium ion; response to corticosterone stimulus; response to DNA damage stimulus; response to drug; response to estradiol stimulus; response to ethanol; response to iron ion; response to magnesium ion; response to organic nitrogen; response to vitamin E; response to X-ray; transcription, DNA-dependent; unfolded protein response; Wnt receptor signaling pathway through beta-catenin
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.